Renaissance Technologies LLC lowered its holdings in shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) by 81.0% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 55,160 shares of the life sciences company’s stock after selling 235,340 shares during the period. Renaissance Technologies LLC’s holdings in Integra Lifesciences were worth $3,553,000 as of its most recent filing with the SEC.

Other institutional investors have also bought and sold shares of the company. Zeke Capital Advisors LLC acquired a new position in shares of Integra Lifesciences during the 2nd quarter worth $204,000. Eagle Boston Investment Management Inc. acquired a new position in shares of Integra Lifesciences during the 2nd quarter worth $223,000. Hsbc Holdings PLC acquired a new position in shares of Integra Lifesciences during the 1st quarter worth $235,000. World Asset Management Inc acquired a new position in shares of Integra Lifesciences during the 2nd quarter worth $261,000. Finally, LS Investment Advisors LLC raised its holdings in shares of Integra Lifesciences by 99.3% during the 2nd quarter. LS Investment Advisors LLC now owns 4,276 shares of the life sciences company’s stock worth $275,000 after buying an additional 2,130 shares in the last quarter. 84.43% of the stock is owned by institutional investors.

A number of research firms have recently commented on IART. Morgan Stanley set a $68.00 price target on Integra Lifesciences and gave the stock a “hold” rating in a report on Thursday, October 11th. Citigroup cut Integra Lifesciences from a “buy” rating to a “neutral” rating and upped their target price for the stock from $64.00 to $66.00 in a report on Monday, July 2nd. Zacks Investment Research cut Integra Lifesciences from a “buy” rating to a “hold” rating in a report on Tuesday, June 26th. BTIG Research reaffirmed a “buy” rating and issued a $69.00 target price on shares of Integra Lifesciences in a report on Thursday, October 11th. Finally, BidaskClub raised Integra Lifesciences from a “hold” rating to a “buy” rating in a report on Friday. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating and five have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $62.15.

Shares of IART opened at $62.58 on Friday. Integra Lifesciences Holdings Corp has a 12-month low of $41.51 and a 12-month high of $67.50. The company has a quick ratio of 2.27, a current ratio of 3.52 and a debt-to-equity ratio of 1.10. The stock has a market capitalization of $5.42 billion, a price-to-earnings ratio of 32.49, a PEG ratio of 1.96 and a beta of 0.57.

Integra Lifesciences (NASDAQ:IART) last issued its earnings results on Wednesday, July 25th. The life sciences company reported $0.60 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.60. The business had revenue of $366.20 million during the quarter, compared to analysts’ expectations of $368.08 million. Integra Lifesciences had a return on equity of 17.43% and a net margin of 5.10%. The business’s revenue for the quarter was up 29.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.45 EPS. As a group, research analysts forecast that Integra Lifesciences Holdings Corp will post 2.4 earnings per share for the current fiscal year.

In other news, insider Jeffrey Mosebrook sold 1,000 shares of the stock in a transaction dated Friday, August 10th. The stock was sold at an average price of $62.42, for a total value of $62,420.00. Following the completion of the sale, the insider now owns 3,085 shares of the company’s stock, valued at $192,565.70. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Glenn Coleman sold 8,916 shares of the stock in a transaction dated Thursday, August 9th. The shares were sold at an average price of $63.00, for a total value of $561,708.00. Following the completion of the sale, the vice president now directly owns 16,795 shares of the company’s stock, valued at approximately $1,058,085. The disclosure for this sale can be found here. In the last three months, insiders sold 126,463 shares of company stock valued at $8,013,188. Insiders own 5.10% of the company’s stock.

Integra Lifesciences Company Profile

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Featured Story: Understanding Analyst Recommendations

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra Lifesciences Holdings Corp (NASDAQ:IART).

Institutional Ownership by Quarter for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.